Department of Hematology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea.
Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul. St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Bone Marrow Transplant. 2018 Oct;53(10):1270-1277. doi: 10.1038/s41409-018-0154-0. Epub 2018 Mar 21.
Data regarding the optimal approach for second allogeneic hematopoietic stem cell transplantation (HSCT) after graft failure (GF) in acquired severe aplastic anemia (SAA) are still limited and heterogeneous. We examined 24 patients who underwent second HLA-matched sibling donor (MSD) peripheral blood HSCT for GF. The reconditioning regimen (TNI-750/ATG) consisted of a single dose of total nodal irradiation (TNI, 750 cGy) and antithymocyte globulin (ATG; Thymoglobulin, 1.25 mg/kg/day for 3 days). All but one patient achieved successful engraftment of neutrophils (median 12 days, range 5-21) and platelets (median 15 days, range 9-316). Two patients with subsequent secondary GF achieved successful engraftment after a third HSCT from the same MSD. After a median follow-up of 57.4 months (range, 11.2-155.2), the 5-year overall survival and failure-free survival were 95.7% (95% confidence interval [CI] 87.7-100%) and 87.5% (95% CI 75.2-100%), respectively. One patient developed grade II acute graft-versus-host disease (GVHD), and the 2-year cumulative incidence of chronic GVHD was 23.5% (95% CI 8.1-43.5%). This study demonstrated successful outcomes following a second MSD HSCT in SAA after GF, and the results suggest TNI-750/ATG is a feasible reconditioning option. Future studies with larger cohorts will validate our results.
关于获得性重型再生障碍性贫血(SAA)在移植物失败(GF)后进行第二次同种异体造血干细胞移植(HSCT)的最佳方法的数据仍然有限且存在异质性。我们检查了 24 例因 GF 而行第二次 HLA 匹配的同胞供者(MSD)外周血 HSCT 的患者。预处理方案(TNI-750/ATG)包括单次全淋巴结照射(TNI,750 cGy)和抗胸腺细胞球蛋白(ATG;Thymoglobulin,1.25 mg/kg/天,连用 3 天)。除 1 例患者外,所有患者均成功植入中性粒细胞(中位数 12 天,范围 5-21)和血小板(中位数 15 天,范围 9-316)。2 例随后发生继发性 GF 的患者在同一 MSD 进行第三次 HSCT 后成功植入。中位随访 57.4 个月(范围 11.2-155.2)后,5 年总生存率和无失败生存率分别为 95.7%(95%置信区间 [CI] 87.7-100%)和 87.5%(95% CI 75.2-100%)。1 例患者发生 II 级急性移植物抗宿主病(GVHD),2 年慢性 GVHD 的累积发生率为 23.5%(95% CI 8.1-43.5%)。本研究表明,在 SAA 因 GF 后进行第二次 MSD HSCT 可获得成功结果,并且结果表明 TNI-750/ATG 是一种可行的预处理选择。未来更大队列的研究将验证我们的结果。